Get started
Author

Yi Cheng Zhu

The Association between Serum Uric Acid Levels and the Prevalence of Vulnerable Atherosclerotic Carotid Plaque: A Cross-sectional Study
2015 · Qing Li, Yong Zhou, et al. · Scientific Reports · 53
PDF
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al. · Clinical Cancer Research · 19
PDF
A Novel Mutation in COL4A1 Gene in a Chinese Family with Pontine Autosomal Dominant Microangiopathy and Leukoencephalopathy
2021 · Qing Li, Chengfeng Wang, et al. · Translational Stroke Research · 19
PDF
Predictive Value of Multiple Scoring Systems in the Prognosis of Septic Patients with Different Infection Sites: Analysis of the Medical Information Mart for the Intensive Care IV Database
2024 · Di Zhang, Changyong Wang, et al. · Biomedicines · 13
Multidetector computed tomography in the diagnosis of spontaneous isolated superior mesenteric artery dissection: changes in diameter on nonenhanced scan and stent treatment follow-up
2019 · Weiqiang Yan, Rong Huang, et al. · Journal of International Medical Research · 11
An Evaluating Method for Autonomic Nerve Activity by Means of Estimating the Consistency of Heart Rate Variability and QT Variability
2014 · Yi Zhu, Xiaolin Yang, et al. · IEEE Transactions on Biomedical Engineering · 10
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
2025 · Yan Huang, Li Zhang, et al. · Journal of Clinical Oncology · 9
Imaging angiogenesis using 68 Ga-NOTA-PRGD2 positron emission tomography/computed tomography in patients with severe intracranial atherosclerotic disease
2017 · Shi Shu, Li Zhang, et al. · Journal of Cerebral Blood Flow & Metabolism · 8
T2-Weighted Whole-Brain Intracranial Vessel Wall Imaging at 3 Tesla With Cerebrospinal Fluid Suppression
2021 · Lei Zhang, Yanjie Zhu, et al. · Frontiers in Neuroscience · 6
PDF
[Effect of electroacupuncture of "Hegu" (LI 4)-"Taichong" (LR 3) on colonic nitric oxide synthase and glutathione peroxidase activity and nitric oxide content in depression rats].
2008 · Xue-Kuan Huang, Lian-Shi Zhuo, et al. · PubMed · 5
Distinguishing heart failure subtypes: the diagnostic power of different cardiac magnetic resonance imaging parameters
2024 · Yanhui Hao, Rui Zhang, et al. · Frontiers in Cardiovascular Medicine · 3
PDF
EpiGuide 2D: visibility assessment of a novel multi-channel out-of-plane needle guide for 2D point of care ultrasound
2019 · Simon Honigmann, Yi Cheng Zhu, et al. · SPIE Medical Imaging: Image-Guided Procedures, Robotic Interventions, and Modeling · 2
Clinical application of superior laryngeal nerve block combined with thyrocricocentesis tracheal surface anesthesia in emergency tracheal cannulation for cerebral trauma
2017 · Dongnan Yu, Yi Zhu, et al. · Biomedical Research-tokyo · 1
[Association between sequence variation of Furin gene and obesity in ethnic Kazakh from Xinjiang].
2013 · Hong-mei Wang, Yan Shen, et al. · PubMed · 1
Figure 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Data from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Figure 3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Figure 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Figure S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Figure S4 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Figure S2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Figure S3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Methods S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
PDF
Supplementary Table S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Table S2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Works count: 43
Citation count: 160
H-index: 8
I10-index: 6
Year
Topic
Type